Earlier this month, Swiss drug major Novartis India sold its three established brands to Dr Reddy's Laboratories and terminated the employment of 400 staffers. In October, US drugmaker Eily Lily sold the marketing rights of its anti-diabetes drugs to Cipla and laid off 120 employees in India. Around the same time, Danish pharma company Lundbeck decided to exit India as part of its global strategy. In 2019, US drug major Pfizer closed two facilities manufacturing injectables in the country in response to falling demand.
Read more at: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/why-mnc-pharma-companies-are-realigning-their-india-operations/articleshow/89757660.cms
Comments